Your prediction
Takeda Pharmaceutical Co Ltd Stock
A loss of -1.100% shows a downward development for Takeda Pharmaceutical Co Ltd.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | -1.100% | -5.208% | 2.175% | 16.620% | 11.400% | 5.545% | 3.446% |
| Santen Pharmaceutical Corp Ltd. | -2.880% | -1.923% | -13.559% | 6.250% | 17.241% | 25.153% | -10.526% |
| Chugai Pharmaceutical Co Ltd | 1.380% | 1.079% | -9.839% | -13.680% | -16.730% | 39.851% | 21.847% |
| Eisai Co Ltd | -5.090% | 0.895% | 12.246% | 1.646% | 1.725% | -54.698% | -62.676% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook